An Indian Scenario: Emerging Advances in Nanotechnology as Drug Delivery System in Rheumatoid Arthritis

U.B. Wahul¹ , L.H Kamble² , A.S. Kadam³

1. School of life Sciences, Swami Ramanand Teerth Marathwada University, Nanded, India.
2. School of life Sciences, Swami Ramanand Teerth Marathwada University, Nanded, India.
3. Dept. of Botany, DSM Arts, Commerce, Science College, Jintur, India.

Correspondence should be addressed to: lhkamble@gmail.com.

Section:Research Paper, Product Type: Isroset-Journal
Vol.5 , Issue.1 , pp.28-32, Feb-2018

CrossRef-DOI:   https://doi.org/10.26438/ijsrbs/v5i1.2832

Online published on Feb 28, 2018

Copyright © U.B. Wahul, L.H Kamble, A.S. Kadam . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

589 Views    222 Downloads    165 Downloads

Abstract :
There are several significant assays including bioavailability, Toxicity, high clearance, and further current therapies require higher and frequent dosing to gain desired therapeutic effects for Rheumatoid arthritis (RA). Nanoparticles have been widely investigated for rheumatoid arthritis (RA). Though, higher doses of Nanocarriers also increase the incidence of dreadful adverse effects. Wherever, nanocarrier properties are most populated by the use of different approaches like targeting ligands, to change the physicochemical properties including higher encapsulation, better penetrating ability in cells etc. The main advantage of the nanocarrier that they provide longer circulation which enhances drug localization at the inflamed site and selective targeting to enhance the therapeutic index of anti-arthritic drugs. However, the optimal properties of nanocarrier also depend on the route of administration and size of particles, thus larger size show more retention upon local injection and smaller sized ones are more optimal for passive targeting. The present article discusses the emergence of nano-carriers for anti-rheumatic drugs, which delivers drug molecule to the inflamed site by topical, intra-articular (i.a) and intra-venous (i.v) administration to take advantage of therapeutic efficacy by passive and active drug delivery. Advancements have been made extensively but still better investigations are needed to achieve the risk-benefit ratio for the development of safe, stable and effective targeting nanocarriers for the e treatment of rheumatoid arthritis (RA).

Key-Words / Index Term :
Rheumatoid Arthritis, Topical delivery, Transferosomes, Nanomedicine, Liposomes, Nanocarrier

References :
[1] D.Reddy, L.W.Trost, T.Lee, A.Baluch, A.D Kay; Rheumatoid Arthritis: Current Pharmacologic Treatment and Anasthteic onsiderations, M.E.J. ANESTH Vol.19, Issue (2), 2007.
[2] Kislay Roy, Rupinder Kaur Kumar, Jagat Rakesh Kumar; Molecular targets in arthritis and recent trends in nano therapy; International journal of Medicine; Vol.10, Issue 1, pp.5407-5420, 2015.
[3] Cross M, Smith E, Hoy D, et al, The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study; Annals of the Rheumatic Diseases;Vol.73; pp.1316-1322, 2014.
[4] R.Handa, U.R.K. Rao, Juliana F.M Lewis, Gautam Rambhad, Susan Shiff, Canna J.Ghia; Literature review of rheumatoid arthritis in India; International journal of Rheumatic Diseases; Vol.19, Issue 5, pp.440-451. 2016.
[5] van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrex¬ate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum.;Vol. 65, Issue.(3), pp. 559–570, 2013.
[6] Wiesenthal A, Hunter L, Wang S, Wickliffe J, Wilkerson M. Nanopar¬ticles: small and mighty. Int J Dermatol.;Vol. 50 Issue: (3), pp. 247–254, 2011.
[7] Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology.; Vol. 151, Issue. (2):pp. 458–465, 2010.
[8] Koel Chaudhury, Vishu Kumar, Jayaprakash Kandasamy, Sourav Roy Choudhury; “Regenerative nanomedicine: current perspectives and future directions”. International Journal of Nanomedicine: Vol. 9 pp. 4153–4167, 2014.